Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12726703 | 0.91 | TLR7 (0.60) | TLR7CYP3A4CYP2D6 | |
| SCHEMBL12726738 | 0.90 | TLR7 (0.62) | TLR7CYP3A4CYP2D6 | |
| SCHEMBL12726830 | 0.88 | TLR7 (0.55) | TLR7CYP3A4CYP2D6 | |
| SCHEMBL12726832 | 0.86 | TLR7 (0.52) | TLR7CYP3A4CYP2D6 | |
| SCHEMBL12726716 | 0.86 | TLR7 (0.64) | TLR7CYP3A4CYP2D6 | |
| SCHEMBL12726731 | 0.86 | TLR7 (0.64) | TLR7CYP3A4CYP2D6 | |
| SCHEMBL12726799 | 0.85 | TLR7 (0.54) | TLR7CYP3A4CYP2D6 | |
| SCHEMBL12726805 | 0.85 | TLR7 (0.56) | TLR7CYP3A4CYP2D6 | |
| SCHEMBL12726751 | 0.85 | TLR7 (0.56) | TLR7CYP3A4CYP2D6 | |
| SCHEMBL12726811 | 0.84 | TLR7 (0.53) | TLR7CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491035-B1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES INC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9161934-B2 | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections | GILEAD SCIENCES, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9161934-B2 | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections | GILEAD SCIENCES, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150126509-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2015-05-07 | — | — | US | disclosed |
| US-20150126509-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2015-05-07 | — | — | US | disclosed |
| US-8962652-B2 | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections | GILEAD SCIENCES, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962652-B2 | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections | GILEAD SCIENCES, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140128389-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128389-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8507507-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507507-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20110098248-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2011049825-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110098248-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126509-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | ENTPD5, MAVS, TPMT | TLR7 25/4885CYP3A4 3033/4885CYP2D6 2559/4885 |
| US-20140128389-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | ENTPD5, MAVS, TPMT | TLR7 25/4885CYP3A4 3033/4885CYP2D6 2559/4885 |
| US-20110098248-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR6, TLR1 | TLR7 9/4885CYP3A4 4822/4885CYP2D6 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.